An alternative strategy to reduce estrogen signaling in ER-positive breast cancer is through the inhibition of aromatase, an enzyme typically expressed in fat, stromal and muscle tissue but also breast cancer, responsible for converting androgens into estrogen (78). The gene discussed is CYP19A1; the disease is breast carcinoma.